Ajinomoto Co., Ltd.

Nihon Kohden Corporation

Drug Delivery System Institute, Ltd.

Tadamitsu Kishimoto

Other

Yoshiyuki Takahara

Hiroshi Matsui

Yutaka Nagai

Akira Okano

Toshio Hirano

Katsuhiro Tsuchiya

Takami Maekawa

Yukio Akiyama

Masao Yamazaki

Masayo Date

Naoyuki Yamada

Yoshiteru Hirose

Masao Motoki

Hisao Fukuda

Akira Mitsui

Manabu Suzuki

Daisuke Ejima

Yutaka Sato

Sawao Murao

Masanobu Yatagai

Takao Kida

Hiroshi Mizuno

Chieko Ejima

Yoko Takeuchi

Toshiro Shida

Asao Murai

Maiko Mori

Tomohisa Okutsu

Zuisho Terahara

Masatsune Kainosho

Fumihiko Yokoya

Haruya Sato

Eiko Hayashi

Tomoyuki Tabata

Kumiko Hamada

Mayumi Watanabe

Each gene in a group comprising many genes is cloned into an expression vector so that its gene product should be expressed as a fusion protein with a protein emitting self-fluorescence to construct a gene expression library. The gene expression library is introduced into cells of two groups to express the fusion proteins in the cells, and only one cell group is stimulated by a drug or the like. Then, cells in which the fusion proteins are localized in the nuclei or their nuclei are isolated from cells of the two groups, respectively. By comparing these cells, genes coding for proteins that are transported into the nuclei specifically in response to a certain stimulus when the stimulus is applied to the cells are retrieved.

Method of searching for gene encoding nuclear transport protein

An isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 11, wherein the expression of said polypeptide is significant lower specifically in human livers with hepatitis compared with that in human health livers. The detection of said polypeptide expression in human liver can be used as a diagnosis for human hepatitis.

Polypeptides, use thereof and process for producing the same

In gene expression frequency analysis, a vector primer to which each cDNA is ligated is formed by synthesizing the cDNA from each mRNA using by a vector primer having a poly(T) sequence; each cDNA sequence is converted to a tag on the vector primer; a concatemer is formed by ligating the obtained tags via a sequence that enables recognition of ends of the tags; and the nucleotide sequence of the concatemer is analyzed.

Method for analyzing gene expression frequency

The present invention relates to a modified physiologically active protein, modified physiologically active proteins produced by the process and pharmaceutical compositions containing the same.

Modified physiologically active proteins and medicinal compositions containing the same

A flow cell , a composite lens , and first to third detectors to are arranged in this sequence in the light pathway of light emitted from a laser light source . The composite lens is configured by a convex lens , and lens elements and . These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element to be collected thereby, and is then received by the second detector . Forward large angle scatter having a large scattering angle impinges on the second lens element in the outermost periphery to be collected thereby, and is then received by the third detector which is remotest from the composite lens.

Particle analyzer and composite lens formed by integrally joining plural lens elements of different focal points

A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

Particle analyzer and composite lens formed by integrally joining plural

The present invention relates to a process for producing a conjugate of a biologically active peptide or protein having at least one glutamine residue with a high-molecular weight substance containing an amino group. The present invention also relates to a composite of this conjugate with a nucleic acid adsorbed thereto for transferring nucleic acids to mammalian cells.

Modified protein for gene transfer and process for producing the same

Modification of peptide and protein

There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ion exchange chromatographic treatment and a reversed phase HPLC step, in combination (i) or (ii). According to these purification processes, it becomes possible to remove the impurities derived from a microorganism and human BCDF analogs, and the thus obtained natural type human BCDF has a high purity and can be utilized for pharmaceutical preparations.

Method of purification of human BCDF

A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, and compositions containing the BCDF are disclosed.

Recombinant process of producing non-glycosylated B-cell defferentiation

A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, compositions containing the BCDF and various therapeutic uses are disclosed.

Use of recombinant B-cell differentiation factor for augmenting antibody

A highly retrovirus-producing DNA construct, which comprises a gene encoding retrovirus which is incorporated into a vector for gene amplification.

Highly retrovirus-producing DNA construct and cell line

A composition and a method for supporting bone marrow transplantation are disclosed. The composition comprises a therapeutically acceptable amount of human B cell differentiation factor, or its biological equivalent, optionally in combination with an auxiliary agent selected from IL-1, IL-3, IL-4, IL-5, G-CSF, GM-CSF, and M-CSF. The composition also promotes the proliferation of hematopoietic cells in vitro.

Composition and method for supporting bone marrow transplantation

A purified ring peptide antibiotic of the following empirical formula:

Ring peptide antibiotics, Permetin A and a process for producing the same

Growing community of inventors

Kawasaki, Japan

Yoshiyuki Takahara